Video visits to check skin rashes caused by cancer treatment
Tests video consultations for assessing skin problems from cancer treatments.
Plain-language title generated from the registry record
Registry title: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
Key facts
- Where
- Sligo, IrelandSee the site
Where in Ireland
- Sligo University HospitalSligo, IrelandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sligo General Hospital
- Trial code
- NCT07476807
- Record updated
- 28 April 2026
- Original description
This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.Read full original descriptionShow less
TREATS: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.
Inclusion: Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT); New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT; Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria; Clinically stable condition not requiring urgent in-person evaluation; Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations.
Exclusion: Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria; Clinical status requiring urgent or immediate face-to-face medical assessment; Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects; Inability to access or effectively use the required telemedicine technology.